acalabrutinib

Latest Posts

First and solely BTK inhibitor to display favorable general survival pattern vs. standard-of-care chemoimmunotherapy...

Market

CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy decreased the chance of illness development or dying by 27% vs. customary of care in sufferers with untreated mantle...